GovChime
Notice ID: ca678bdac266410c85e7d909803d8f79Presolicitation

Notice of Intent to Sole Source to Immport Therapeutics, Inc.

Archived on August 21, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
1:00 PM UTC−04:00
Posted
August 19, 2020
Notice type
Presolicitation
Agency
Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION

Notice details

Office
CDC NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES
Place of performance
Atlanta, GA, 30329
Last updated
Apr 29, 2026

Identifiers

Solicitation number
75D301-20-Q-72498
Notice ID
ca678bdac266410c85e7d909803d8f79

Description

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to Immport Therapeutics, Inc d/b/a Antigen Discovery Inc, for the project entitled Identification of Brucella canis and B. abortus RB51 Seroreactive Proteins and Serology Assay Development. Brucella strains such as B. abortus, B. melitensis, and B. suis have an O-specific polysaccharide as part of the outer membrane lipopolysaccharide (LPS) and are designated as "smooth" strains. In contrast, other strains such as B. canis, B. ovis, and RB51, are missing the O-specific polysaccharide from the LPS and are designated as "rough" strains. The lack of this O-antigen from the LPS of the rough strains means that standard Brucella serological assays do not detect antibody against rough strains. There is a critical need to find specific, immunogenic markers whose epitopes can be analyzed, synthesized and developed into optimized serological diagnostic assays. The goal of this project is to develop serodiagnostic assays for detection of human antibodies against rough Brucella strains such as B. canis and RB51, which are known human pathogens. Antigen Discovery Incorporated (ADI) has pioneered the development of expressible open reading frame (ORF) libraries for infectious organisms and has exploited in vitro transcription and translation (IVTT) for production of proteomic microarray chips used for antibody profiling/biomarker discovery. ADI has developed a high-throughput polymerase chain reaction ("PCR")/recombination cloning and expression system that enables the construction of protein microarrays for any organism whose genome sequence has been determined and where a source of genomic DNA is available. This proprietary technology has been utilized to construct protein microarray chips of entire pathogen proteomes in order to interrogate human humoral responses to these pathogens. ADI has recently developed a customizable Brucella protein microarray. This protein microarray contains surface and cytoplasmic proteins specific to the genomes of specifically selected Brucella isolates in a cell-free E. coli IVTT system. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations; however, all quotations/responses received within three (3) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to Contract Specialist at pyx9@cdc.gov by 12pm EST on 8-21-2020.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75D301-20-Q-72498
  1. Pre-Solicitation

Formal solicitation typically follows within 30–60 days. (estimate)

  1. Pre-SolicitationCurrentAug 19, 2020

    Notice of Intent to Sole Source to Immport Therapeutics, Inc.

    Notice ca678bdac266410c85e7d909803d8f79 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

75D301-20-Q-72498

Archive Date

Aug 21, 2020

Office Address

Atlanta, GA, 30333